Allergy Immunotherapy Drops Side Effects: Drops vs. Tablets Explained

No — allergy immunotherapy drops are not individually FDA-approved in the United States. FDA-approved sublingual immunotherapy products are exclusively tablets: Grastek (timothy grass, approved 2014), Ragwitek (short ragweed, approved 2014), Odactra (house dust mite, approved 2017), and Palforzia (peanut, approved 2020). Sublingual drops are compounded by allergists and pharmacies from FDA-approved bulk allergen extracts — legally available as a compounded, off-label prescription but without the individual product approval pathway that tablets completed. This regulatory distinction affects how safety data is collected: tablet safety data comes from large FDA-required Phase III trials; drop safety data comes primarily from European RCTs and WAO position paper analyses. Clinically, the adverse event profile supported by European evidence is comparable to tablets, and WAO considers both approaches evidence-based.

The key differences between compounded allergy drops and FDA-approved tablets are formulation, allergen coverage, and regulatory oversight. FDA-approved tablets contain a single, standardized allergen at a fixed dose — grass, ragweed, or dust mite — with consistent potency across manufacturing batches verified through FDA review. Compounded drops can contain multiple allergens in a single formulation, making them practical for polysensitized patients. Drops concentrate can vary between compounding pharmacies in terms of allergen content, glycerin levels, and overall potency — unlike the standardized tablet dosing. This variability is clinically relevant: switching between compounding pharmacies or lot numbers should be approached with the same caution as a new-vial transition in SCIT, potentially requiring dose reduction. European EAACI guidelines for SLIT drops recommend standardized concentrations to minimize this variability.

Yes — the safety of SLIT drops is supported by extensive European clinical evidence spanning over three decades. The World Allergy Organization's 2013 Position Paper, published in World Allergy Organ Journal 2014 by Canonica et al., synthesizes safety data from 314,959 SLIT doses analyzed across European trials, documenting a systemic reaction rate of 0.056% per dose. Multiple European RCTs for grass, dust mite, and tree pollen SLIT drops have reported oral-local reaction profiles comparable to tablets, with no fatalities. The European Academy of Allergy and Clinical Immunology (EAACI) guidelines endorse drops alongside tablets as evidence-based SLIT approaches. No SLIT fatality — drops or tablets — has ever been confirmed in the published literature. The US regulatory gap reflects the practical difficulty of submitting drug applications for compounded formulations, not a safety concern specific to drops.

Yes — one of the practical advantages of compounded SLIT drops over FDA-approved tablets is the ability to include multiple allergens in a single formulation. This is particularly relevant for polysensitized patients — those allergic to grass, dust mite, cat dander, tree pollen, and other allergens simultaneously. FDA-approved tablets are single-allergen products; you cannot combine Grastek (grass) and Odactra (dust mite) into one tablet. Compounded drops allow a prescribing allergist to build a customized extract covering multiple relevant triggers from a patient's allergy test results. The safety consideration for multi-allergen formulations: there is less standardized data on the systemic adverse event profile of mixed formulations compared to single-allergen products. European multi-allergen SLIT data generally supports safety comparable to single-allergen drops, but patients with multiple high sensitizations may experience more prominent oral-local reactions during build-up.

Eosinophilic esophagitis (EoE) is an inflammatory esophageal condition characterized by abnormal eosinophil accumulation, presenting primarily as progressive dysphagia (difficulty swallowing) and occasional food impaction. It has been reported in approximately 0.07% of patients in Odactra (dust mite SLIT tablet) clinical trials — roughly 2 of 2,737 patients. For SLIT drops, there are rare case reports but no established incidence rate due to limited systematic surveillance. EoE appears to be specific to the sublingual/swallowed allergen exposure route. The practical guidance: if you develop progressively worsening difficulty swallowing, a sensation of food sticking in the chest, or repeated food impaction events during SLIT treatment, stop drops and contact your allergist for referral to gastroenterology. EoE requires endoscopic evaluation and typically treatment discontinuation. It is rare but worth knowing about before starting any sublingual immunotherapy program.

Uncontrolled asthma is a contraindication to both SCIT and SLIT — but well-controlled asthma is not. The standard practice parameter guidance (Cox et al., JACI 2011) requires that asthma be well-controlled before initiating any form of allergen immunotherapy. The risk calculus for SLIT in asthmatic patients is more favorable than for SCIT: SLIT systemic reactions that involve the respiratory system are rarer in absolute terms, and SLIT's zero confirmed fatality record includes asthmatic patients in clinical trials. The PAT Study (Jacobsen 2007) demonstrated that early SCIT in children with rhinitis and mild asthma actually reduced asthma development at 10-year follow-up. For any patient with asthma, a pre-treatment evaluation of asthma control — including spirometry — is appropriate, and your allergist will confirm candidacy before treatment. With at-home SCIT through Curex, that eligibility screen plus closer monitoring of asthma control during build-up is built into the board-certified allergist's oversight.